Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins

Tumori

Volumn 93, Issue 5, 2007, Pages 473-477

  Vatan, Ozgur ^a   Bilaloglu, Rahmi ^a   Tunca, Berrin ^a   Cecener, Gulsah ^a   Gebitekin, Cengiz ^a   Egeli, Unal ^a   Yakut, Tahsin ^a   Urer, Nur ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b Yedikule Chest Disease and Surgery Education and Research Hospital   (Turkey)

Author keywords

k ras codon 12 mutation; Non small cell lung cancer; p53 mutation; Surgical margins

Indexed keywords

K RAS PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; NUCLEOTIDE SEQUENCE; SENSITIVITY ANALYSIS; TUMOR CELL;

EID: 36749086946     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300511     Document Type: Article

References (40)

1. Toyooka S, Tsuda T, Gazdar AF: The tp53 gene, tobacco exposure and lung cancer. Human Mutational: 229-239, 2003.
2. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer, 37 (suppl 8): 4-66, 2001.
3. http://www.saglik.gov.tr. (Official web site of Ministry of Health of Republic of Turkey).
4. Travis WD, Travis LB, Devesa SS: Lung cancer. Cancer, 75 (Suppl 1): 191-202, 1995.
5. Hashimoto T, Tokuhi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishiwaka Y, Tsuchiya S, Nakagawa K, Hayashi J, Tsuchiya E: p53 null mutations undetected by immunohistochemical staining predict a poor out come with early stage non-small cell lung carcinomas. Cancer Res, 59: 5572-5577, 1999.
6. Jassem J, Jassem E, Jakobkiewicz-Banecka J, Rzyman W, Badzio A, Dziadziuszko R, Kobierska-Gulida G, Szymanowska A, Skrzypski M, Zylicz M: P53 and k-ras mutations are frequent events in microscopically negative surgical margins from patients with non-small cell lung carcinoma. Cancer, 100: 1951-1960, 2004.
7. Boring CC, Squires TS, Tong T, Montgomery S: Cancer Statistics, CA Cancer J Clin, 44:7-26, 1994.
8. Masasyesva BG, Tong BC, Brock MV, Pilkington T, Goldenberg D, Sidransky D, Harden S, Westra WH, Califano J: Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer. Int J Cancer, 113(6): 1022-1025, 2005.
9. Levine AJ: P53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
10. Mao L: Molecular abnormalities in lung carcinogenesis and their potential clinical implications. Lung Cancer, 34 (Suppl 2): 27-34, 2001.
11. Kishimoto Y, Murakami Y, Shirashi M, Hayashi K, Sekiya T: Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res, 52: 4799-4804, 1992.
12. Hatzaki A, Razi K, Anagnostopoulou K, Iliadis K, Kodaxis A, Papaioannou D, Labropoulos S, Vasilaki M, Kosmidis P, Saetta A, Mihalatos M, Nasioulas GA: Modified mutagenic PCR-RFLP method for k-ras codon 12 and 13 mutations detection in NSCLC patients. Mol Cell Probes, 15: 243-247, 2001.
13. Huncharek M, Muscat J, Geschwind JF: K-ras oncogene mutation as a prognostic marker in NSCLC: a combined analysis 881 cases. Carcinogenesis, 20: 1507-1510, 1999.
14. Minamoto T, Masayoshi M, Ze'ev R: K-ras mutation: Early detection in molecular diagnosis and risk assessment of colorectal, pancreas and lung cancers - a review. Cancer Detect Prev, 241: 1-12, 2000.
15. Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P: Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev, 8: 297-302, 1999.
16. Keohavaong P, Lan Q, Gao WM, DeMarini DM, Mass MJ, Li XM, Roop BC, Weissfeld J, Tian D, Judy LM: K-ras mutations in lung carcinomas from nonsmoking women exposed to unvented coal smoke in China. Lung Cancer, 41: 21-27, 2003.
17. Rodenhuis S, Slebos RJ: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res, 52: 2665-2669, 1992.
18. Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S: Prognostic significance of k-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol, 17: 668-675, 1999.
19. Immermann SC, Vaneco RM, Fry W, Head LR, Shields TW: Site of recurrence of patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg, 32: 23-27, 1981.
20. Feld R, Rubenstein L, Weisenburger T: Site of recurrence in resected Stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol, 2: 1352-1358, 1984.
21. Zienolddiny S, Ryberg D, Arab Mo, Skaug V, Hagen A: Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer, 84: 226-231, 2001.
22. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF, Rice JM: Mutations of the k-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res, 55, 2665-2672, 1995.
23. Sanger F, Nicklen S, Caulson AR: DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA, 74, 463-467, 1977.
24. IARC TP53 Mutation Database, available at http://wwwp53.iarc.fr
25. The TP53 Web Site, available at http://p53.free.fr
26. D'amico TA, Aloia TA, Moore MBH, Herndon JE, Brooks KR, Lau CL, Harpole DH: Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg, 69: 882-886, 2000.
27. Bodner SM, Minna JD, D'Amico D, Carbone D, Mitsudom T, Federco J, Buchhagen DL, Nau MM, Gazdar AF, Linnoila RI: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7: 743-749, 1992.
28. Rainov NG, Dobberstein KU, Fittkau M, Bahn H, Holzausen HJ, Gantchev L and Burkert W: Absence of p53 antibodies in sera from glioma patients. Clin. Cancer Res, 1: 775-781, 1995.
29. Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE, Weichselbaum RR: Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res, 2: 755-762, 1996.
30. Trivers GE, De Benedetti VMG, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC: Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res, 2: 1767-1775, 1996.
31. Kihara C, Seki T, Furukawa Y, Yamana H, Kimura Y, Van Schaardenburgh P, Hirata K, Nakamura Y: Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal cancer patients. Jpn J Cancer Res, 91: 190-198, 2000.
32. Ozcelik H, Mousses S , Andrulis IL: Low levels of expression of an inhibitor of cyclin dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res, 1: 907-912, 1995.
33. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T: Detection of ras gene mutations in human lung cancers by SSCP Analysis of PCR Products. Oncogene, 5: 1037-1043, 1990.
34. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF: Mutations of ras genes distinguish a subset of non-small cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene, 6: 1353-1362, 1991.
35. Camps C, Sirera R, Bremnes R, Blasco A, Sancho E, Bayo P, Safont MJ, S'anchez JJ, Tar'on M, Rosell R: Is there a prognostic role of k-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer, 50: 339-346, 2005.
36. Houten VMM, Tabor MP, Brekel MWM, Kummer A, Denkers F, Dijikstra J, Leemans R, Wall I, Snow GB, Brakenhoff RH: Mutated p53 as a molecular marker for the diagnosis of the head and neck cancer. Pathology, 198: 476-486, 2002.
37. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittelman W, Hong WK: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their valur in cancer risk assessment. Nature Med, 2: 682-685, 1996.
38. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Brean K, Epstein JB, Priddy R, Lee ND, Zhang L: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res, 6: 357-362, 2000.
39. Patridge M, Pateromichelakis S, Philips E, Emilion GG, A'H-ern RP, Langdon JD: A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma with in a field of cancerization. Cancer Res, 60: 3893-3898, 2000.
40. Yakut T, Egeli U, Gebitekin C: Investigation of c-myc and p53 gene alterations in the tumor and surgical border tissues of NSCLC and effects on clinicopathologic behavior: By the FISH Technique. Lung, 181: 245-258, 2003.